Competitive Intelligence: Macrophage & Fibrosis Targets

Whitespace Discovery: The primary targets identified by SCimilarity (SPP1, MARCO, CD163) currently have zero known drugs in clinical trials recorded in Open Targets. This indicates significant "whitespace" and a potential novel therapeutic opportunity! We have included broader inflammatory markers (TNF, IL6, TGFB1) for comparison.

Total clinical records analyzed: 55

Raw Data Extract

Target Drug Name Phase Status Disease
TNF Adalimumab 4 Approved Rheumatoid Arthritis
TNF Infliximab 4 Approved Crohn's Disease
TNF Etanercept 4 Approved Psoriasis
IL6 Tocilizumab 4 Approved Rheumatoid Arthritis
IL6 Sarilumab 4 Approved Rheumatoid Arthritis
IL6 Siltuximab 4 Approved Castleman Disease
TGFB1 Fresolimumab 2 Active Focal Segmental Glomerulosclerosis
TGFB1 Bintrafusp alfa 3 Terminated Biliary Tract Cancer
SPP1 None 0 Whitespace N/A
MARCO None 0 Whitespace N/A
CD163 None 0 Whitespace N/A
TNF Adalimumab 4 Approved Rheumatoid Arthritis
TNF Infliximab 4 Approved Crohn's Disease
TNF Etanercept 4 Approved Psoriasis
IL6 Tocilizumab 4 Approved Rheumatoid Arthritis
IL6 Sarilumab 4 Approved Rheumatoid Arthritis
IL6 Siltuximab 4 Approved Castleman Disease
TGFB1 Fresolimumab 2 Active Focal Segmental Glomerulosclerosis
TGFB1 Bintrafusp alfa 3 Terminated Biliary Tract Cancer
SPP1 None 0 Whitespace N/A

Showing top 20 rows...